Reports claimed that Merck & Co. and Intercell AG have suspended a vaccination trial. This vaccination was meant for staph infection and this would cause further research and development and to assess the risk and development of this vaccination on a commercial level.

Companies claimed that an independent data-monitoring committee for the trial recommended this suspension. They want sometime for analysis the vaccine before the trial.

The companies said the committee recommended suspension "pending further analyses of the benefit/risk profile of the vaccine candidate."

The companies said that they would do further research on the vaccine and they would provide updates when their research would be completed.

Earlier research claimed that this vaccine would be used to prevent staphylococcus aureus, a bacterial infection in humans.

Previously Barclays Capital analyst Tony Butler estimated that this vaccine would be launched commercially in the market by 2015 and would generate $1.5 billion in its annual sales.

He also claimed that this suspension did not hurt the company much. It would make the vaccine productive after it is passed through different research layers. However, share prices of the company have gone down a little and reached $33.52 after it lost 15 cents.